Zhe Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhe Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Shiew-Mei Huang
Office of Clinical Pharmacology, Office of Translational Sciences Center for Drug Evaluation and Research, US Food and Drug Administration (OCP/CDER/FDA) Silver Spring Maryland USA
2 shared publications Xiulian Du
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research US Food and Drug Administration (OCP/CDER/FDA) Silver Spring Maryland USA
2 shared publications- Yow‐Ming Wang
Therapeutic Biologics Program, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
2 shared publications - Pei‐Rung Huang
Office of Clinical Pharmacology, Office of Translational Sciences Center for Drug Evaluation and Research, US Food and Drug Administration (OCP/CDER/FDA) Silver Spring Maryland USA
1 shared publication Yow-Ming C. Wang
Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (OCP/CDER/FDA), Silver Spring, USA
1 shared publication
Latest Publications
- 14 April 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (1) , 28-31
Insights into PK ‐Based Bridging for Products Using a Common Autoinjector Platform: A Review of 16 Autoinjectors in 14 Biological License Applications
An emerging proposal suggests that prior findings of pharmacokinetic comparability for one product could be applied to other therapeutic protein products that use the same autoinjector platform. We investigated 16 autoinjectors using one platform and found that (a) pharmacokinetic comparability outcomes varied and (b) these outcomes were not attributable to identified device performance parameters or product viscosity. Further investigations are necessary to support the proposed extrapolation across products sharing the same autoinjector platform.
- 14 April 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (1) , 28-31
Insights into PK ‐Based Bridging for Products Using a Common Autoinjector Platform: A Review of 16 Autoinjectors in 14 Biological License Applications
An emerging proposal suggests that prior findings of pharmacokinetic comparability for one product could be applied to other therapeutic protein products that use the same autoinjector platform. We investigated 16 autoinjectors using one platform and found that (a) pharmacokinetic comparability outcomes varied and (b) these outcomes were not attributable to identified device performance parameters or product viscosity. Further investigations are necessary to support the proposed extrapolation across products sharing the same autoinjector platform.
- 2 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (3) , 404-407
Pharmacokinetics‐Bridging Between Autoinjectors and Prefilled Syringes for Subcutaneous Injection: Case Examples Revealing a Knowledge Gap
Comparative pharmacokinetics (PK) studies have efficiently served as the bridge between autoinjectors and prefilled syringes given the underlying principles that comparable exposure could translate to comparable efficacy and safety. This article discusses approaches used to address uncertainties associated with the observation of noncomparable PK leading to the successful introduction of new autoinjector devices for monoclonal antibody and Fc‐fusion protein products. Information from seven case examples suggests a knowledge gap that warrants attention in autoinjector development.
- 2 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (3) , 404-407
Pharmacokinetics‐Bridging Between Autoinjectors and Prefilled Syringes for Subcutaneous Injection: Case Examples Revealing a Knowledge Gap
Comparative pharmacokinetics (PK) studies have efficiently served as the bridge between autoinjectors and prefilled syringes given the underlying principles that comparable exposure could translate to comparable efficacy and safety. This article discusses approaches used to address uncertainties associated with the observation of noncomparable PK leading to the successful introduction of new autoinjector devices for monoclonal antibody and Fc‐fusion protein products. Information from seven case examples suggests a knowledge gap that warrants attention in autoinjector development.
- 1 November 2023
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (1) , 13-27
A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment
Objective Manufacturing changes occur commonly throughout stages of biologics development and may result in product quality attribute changes. As changes in critical quality attributes have the potential to affect clinical safety and efficacy of products, it is imperative to ensure the quality and clinical performance before introducing the after-change products. Thus, we embarked on this project to understand what data have supported the manufacturing changes for licensed products with pre- and post-approval changes. Methods We surveyed the manufacturing changes of 85 monoclonal antibodies and 10 Fc fusion proteins approved by the Food and Drug Administration as of December 25, 2021. After collecting the type and timing of changes for these products, we investigated the approaches that provided supporting data for the changes. The source documents included reports submitted by applicants and FDA’s regulatory reviews. Results Analytical comparability was assessed to support all identified manufacturing changes. Supporting clinical data were available in 92% of these manufacturing changes; including data from pharmacokinetic comparability studies alone (3%), other studies on efficacy or safety (70%) and a combination of both (19%). Clinical pharmacokinetic comparability data contributed to supporting substantial changes, such as host cell type or master cell bank changes, concentration or formulation changes, and changes from pre-filled syringes to autoinjectors, especially when introduced after completing pivotal studies. Conclusion Our comprehensive retrospective analysis provides an understanding of the regulatory experience and industry practice, which could facilitate developing appropriate comparability approaches to support manufacturing changes in the future.
- 1 November 2023
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (1) , 13-27
A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment
Objective Manufacturing changes occur commonly throughout stages of biologics development and may result in product quality attribute changes. As changes in critical quality attributes have the potential to affect clinical safety and efficacy of products, it is imperative to ensure the quality and clinical performance before introducing the after-change products. Thus, we embarked on this project to understand what data have supported the manufacturing changes for licensed products with pre- and post-approval changes. Methods We surveyed the manufacturing changes of 85 monoclonal antibodies and 10 Fc fusion proteins approved by the Food and Drug Administration as of December 25, 2021. After collecting the type and timing of changes for these products, we investigated the approaches that provided supporting data for the changes. The source documents included reports submitted by applicants and FDA’s regulatory reviews. Results Analytical comparability was assessed to support all identified manufacturing changes. Supporting clinical data were available in 92% of these manufacturing changes; including data from pharmacokinetic comparability studies alone (3%), other studies on efficacy or safety (70%) and a combination of both (19%). Clinical pharmacokinetic comparability data contributed to supporting substantial changes, such as host cell type or master cell bank changes, concentration or formulation changes, and changes from pre-filled syringes to autoinjectors, especially when introduced after completing pivotal studies. Conclusion Our comprehensive retrospective analysis provides an understanding of the regulatory experience and industry practice, which could facilitate developing appropriate comparability approaches to support manufacturing changes in the future.